Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.

Autor: Van Damme P; Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium., Dionne M; Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada., Leroux-Roels G; Centre for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium., Van Der Meeren O; GSK, Wavre, Belgium., Di Paolo E; GSK, Rixensart, Belgium., Salaun B; GSK, Rixensart, Belgium., Surya Kiran P; GSK, Bangalore, India., Folschweiller N; GSK, Wavre, Belgium.
Jazyk: angličtina
Zdroj: Journal of viral hepatitis [J Viral Hepat] 2019 Sep; Vol. 26 (9), pp. 1066-1075. Date of Electronic Publication: 2019 Jun 02.
DOI: 10.1111/jvh.13125
Abstrakt: The duration of protection after hepatitis B vaccination is not exactly known. This phase IV study evaluated antibody persistence and immune memory 20-30 years after adult immunization with recombinant hepatitis B vaccine (HBsAg vaccine, Engerix-B) in routine clinical practice. Men and women 40-60 years old, with documented evidence of vaccination with three or four HBsAg vaccine doses 20-30 years earlier and without subsequent booster, were enrolled and received HBsAg vaccine as challenge dose. HBsAg-specific antibodies (anti-HBs) and frequencies of HBsAg-specific circulating memory B cells and CD4 + T cells expressing combinations of activation markers (CD40L, IL2, IFNγ, TNFα) were measured prechallenge, 7 and 30 days postchallenge. Of 101 participants in the according-to-protocol cohort for immunogenicity, 90.1% had anti-HBs concentrations ≥ 10 mIU/mL prechallenge administration; 84.2% and 100% mounted an anamnestic response 7 and 30 days postchallenge, respectively. HBsAg-specific memory B and CD4 + T cells expressing at least two activation markers were low prechallenge and increased markedly postchallenge. These results suggest sustained immune memory and long-term protection 20-30 years after a complete primary HBsAg vaccination course during adulthood, in line with current recommendations that a booster is not needed in fully vaccinated immunocompetent adults.
(© 2019 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje